Analyst Downgrades Genomic Health for Lackluster Seasonal Oncotype DX Growth

Nov 02, 2007

NEW YORK (GenomeWeb News) - An analyst for financial services firm Cantor Fitzgerald has downgraded Genomic Health’s stock to a ‘hold’ from a ‘buy’ based on the company’s third-quarter earnings, which were released on Wednesday.

The analyst’s report said growth in Oncotype Dx sales were less than expected within seasonal variation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Drive Resistance

Gene drives might run into biological resistance, the Economist reports.

Dalí DNA Collected

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Synthetic-Conservation Biology Disconnect

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

This Week in Science

In Science this week: full CRISPR locus integration complex structure, and more.

Main menu